JZ

Julian Zachmann

Investor at Family Office

Greater Munich Metropolitan Area

Overview

Work Experience

Family Office

  • Investor

    2023 - Current

EH

EIT Health

  • Startup Mentor

    2021 - 2023

HG

High-Tech Gründerfonds

  • Investment Manager

    2019 - 2023

    Led investments in: • Aignostics: AI-Powered precision diagnostics for Pathology (AI in Pharma R&D) • Cutanos: Dermal targeted delivery systems for immunotherapies (Drug Delivery in Pharma) • DNTOX: Safe chemicals for a healthy brain development without animal experiments (Chemistry) • Invasight: Small molecule against FGFR-driven cancers (Drug Development in Oncology) • Refined Laser Systems: Diagnostics during tumor resection surgery (Microscopy in Pathology) Furthermore represented HTGF in: • Lindis Blood Care: A medical device to remove cancer cells from salvaged blood (MedTech in Surgery) • Mediaire: Diagnostics using MR-data in Neuroradiolgy (AI in Radiology)

UG

UnternehmerTUM GmbH - Center for Innovation and Business Creation at TUM

  • Co-Founder & Artificial Intelligence Engineer

    2018 - 2018

    • Co-founded start-up to automatically monitor recovery process of patients after accidents or operations • Developed prototype using artificial intelligence and computer vision for human body pose detection

RT

Ryvu Therapeutics

  • Senior Scientist

    2016 - 2018

    • Fast tracked to senior scientist position, 2-4 years above my level of experience • Advanced cancer drug project from initiation to tests on human volunteers (clinical phase 1) within 2 years compared to industry average for pre-clinical drug development of ~5 years • Led team of ~25 experimental scientists by data analysis and computer-based predictions resulting in 3 patents for 2 separate cancer drug projects within 2 years • Developed in-house software achieving similar results to commercial software licensed for $50K per year which significantly improved research quality without increasing costs for software licenses • Automated workflows in the Computational Drug Discovery department to standardize and speed-up development processes significantly improving R&D

MS

MELiSSA Space Research Program

  • Contributor

    2012 - 2013

    • Part-time contributor to the MELiSSA Space Research Program during my PhD • Production of primary matter within permitted limits of quantity, quality, and time allowing for the successful development of the project

Education

Relevant Websites